Texas-based genetic medicines company ReCode Therapeutics has received USD 15 million from the Cystic Fibrosis Foundation (CF Foundation). The financial backing supports the company's research collaboration with Intellia Therapeutics for cystic fibrosis treatment.

The granted funding will accelerate research and advancements in ReCode's gene correction efforts. The main focus aligns with producing potential therapeutics for cystic fibrosis patients, particularly those unresponsive to approved CFTR modulators. The funding aims to aid three unique gene correction programs to address cystic fibrosis mutations not treated by current therapies.

Analyst QuickTake: The partnership between ReCode and Intellia was initiated in February 2024 to leverage Intellia's CRISPR-based gene-editing platform, including its DNA writing technology, alongside ReCode's selective organ targeting (SORT) lipid nanoparticle (LNP) delivery system to precisely correct CF-causing gene mutations. In June 2024 , ReCode reported results from its preclinical program, RCT-2100, demonstrating that the inhaled gene therapy successfully corrected a CF-causing mutation in lung cells derived from CF patients.